ACG unveils patent-clean laminate ‘DryPod’ to shake up moisture-protection market
R&D

ACG unveils patent-clean laminate ‘DryPod’ to shake up moisture-protection market

The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules

  • By IPP Bureau | November 23, 2025

ACG, the global giant in solid-dosage and packaging solutions, has launched DryPod, a new desiccant-based cold-form laminate that aims to upend a market long dominated by a single rigid, patented technology.

The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules while slashing the compatibility and supply-chain headaches that have plagued pharmaceutical manufacturers for years.

For drugmakers, moisture control is non-negotiable: without it, potency drops and shelf life suffers. But current solutions depend largely on one co-extrusion technology, locking manufacturers into specific foils, lengthy lead times, and limited machine compatibility. ACG claims DryPod breaks that bottleneck.

Built with a proprietary lamination process, DryPod is designed to run seamlessly on standard blister-forming lines — no retrofits, no workflow overhauls. Manufacturers can also use it with any PE-sealable lidding foil, a shift that promises to widen supplier choice and smooth global procurement.

One of DryPod’s most significant selling points: its patent-clean architecture. By avoiding overlap with active patents in the desiccant co-extrusion space, ACG says it removes the legal uncertainty that has discouraged companies from switching suppliers or scaling production across regions.

Backed by ACG’s global technical support network, the new laminate is positioned as a plug-and-play solution for manufacturers handling moisture-sensitive molecules at scale.

“DryPod is built for the realities of modern pharmaceutical manufacturing,” said Dr. Akbar Ali, General Manager and Head of Development and Technologies at ACG. “Manufacturers have faced years of constraints due to rigid technologies and supply limitations. DryPod directly addresses these challenges, empowering innovators to bring critical therapies to market more efficiently and reliably.”

With DryPod now commercially available worldwide, ACG is pitching the launch as another step in its push to make pharmaceutical production safer, more efficient, and more adaptable in a fast-evolving global market.

Upcoming E-conference

Other Related stories

Startup

Digitization